Accelerate your CDMO or DTC pipeline. Map the exact physiochemical constraints, bioavailability synergies, and optimal delivery mechanisms for Echinacea purpurea (Cichoric acid).
Cichoric acid acts as a potent immunomodulator and hyaluronidase inhibitor, enhancing phagocytosis and stimulating the proliferation of T-lymphocytes to bolster innate and adaptive immune responses.
5281764
474.4 g/mol
2
(2R,3R)-2,3-bis[[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]butanedioic acid
Every active compound behaves uniquely based on the physical matrix it is suspended in. Below are the known physical chemistry challenges for Echinacea purpurea (Cichoric acid) across standard consumer modalities.
The hygroscopic nature of Echinacea extracts requires moisture-resistant HPMC capsules to prevent clumping and degradation of the phenolic content.
The high acidity and phenolic profile of cichoric acid can interfere with pectin gelation kinetics, potentially leading to a soft or unstable matrix.
The significant dosage required for therapeutic efficacy exceeds the standard 20-40mg payload capacity of thin-film polymer matrices.
Ready to launch a product featuring Echinacea purpurea (Cichoric acid)? Skip months of expensive wet-lab iterations. Generate a manufacturer-ready formulation in hours, instantly screened for physical incompatibilities and global regulatory compliance.
Build Science-Backed FormulationNeed absolute proof that your Echinacea purpurea (Cichoric acid) extract actually absorbs? Stop blindly combining generic powders. Run a physics-based PBPK simulation to mathematically engineer peak clinical efficacy and targeted plasma concentrations.
Simulate BioavailabilityIs your Echinacea purpurea (Cichoric acid) payload degrading in the capsule before the expiration date? Stop waiting for costly bench testing. Run an accelerated digital twin to precisely model oxidation pathways and pH shifts before finalizing a manufacturing run.
Model Active Degradation